Evidence map›Paper›PMID 34013274›Full record

ArticlebioRxiv : the preprint server for biology2021

Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents.

Hoda Zarkoob, Anna Allué-Guardia, Yu-Chi Chen, Olive Jung, Andreu Garcia-Vilanova, Min Jae Song, Jun-Gyu Park, Fatai Oladunni, Jesse Miller, Yen-Ting Tung and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 12 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Hoda Zarkoob *3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.
Anna Allué-Guardia *Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX.
Yu-Chi Chen3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.
Olive Jung3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.
Andreu Garcia-VilanovaHost-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX.
Min Jae Song3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.
Jun-Gyu ParkHost-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX.
Fatai OladunniHost-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX.
Jesse MillerDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA.
Yen-Ting Tung3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.
Ivan KosikNational Institute for Allergies and Infectious Diseases, National Institutes of Health, Bethesda, MD.
David SchultzDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA.
Jonathan YewdellNational Institute for Allergies and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Jordi B TorrellesHost-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX.
Luis Martinez-SobridoHost-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX.
Sara CherryDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA.
Marc Ferrer3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.
Emily M Lee3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.
National Institutes of Health · USTexas Biomedical Research Institute · USUniversity of Pennsylvania · USHigh Throughput Biology (United States) · US

Funding

Immunobiology and Virology of Influenza A VirusZIAAI001211 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI YEWDELL, JONATHAN W · 2016 to 2025
$10.4M
SARS-CoV2 Immunity and Cell BiologyZIAAI001320 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI YEWDELL, JONATHAN W · 2020 to 2024
$1.7M
COVID-19: 3D Bioprinted Tissue Models for Respiratory VirusesZIATR000414 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI FERRER, MARC · 2020 to 2024
$1.1M
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the third coronavirus in less than 20 years to spillover from an animal reservoir and cause severe disease in humans. High impact respiratory viruses such as pathogenic beta-coronaviruses and influenza viruses, as well as other emerging respiratory viruses, pose an ongoing global health threat to humans. There is a critical need for physiologically relevant, robust and ready to use,

Identifiers

PMID34013274
PMCPMC8132232
OpenAlexW3160542397

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.